SCHEMBL390202

SCHEMBL390202

NC(=O)c1ccc(Oc2ccc3c(c2)CC(NCCc2cccc(F)c2)CC3)nc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.52
ADRB3 P13945 1/20 0.52
OPRM1 P35372 14/20 0.52
OPRD1 P41143 13/20 0.52
OPRK1 P41145 12/20 0.51
HRH3 Q9Y5N1 1/20 0.49
GRIN2D O15399 1/20 0.47
GRIN3B O60391 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
GRIN1 Q05586 1/20 0.47
KCNH2 Q12809 1/20 0.47
GRIN2A Q12879 1/20 0.47
GRIN2B Q13224 1/20 0.47
ROCK1 Q13464 1/20 0.47
GRIN2C Q14957 1/20 0.47
GRIN3A Q8TCU5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL385586 0.97 OPRM1 (0.52) ADRB1ADRB3OPRM1OPRD1OPRK1
SCHEMBL390080 0.91 OPRM1 (0.63) ADRB1ADRB3OPRM1OPRD1OPRK1
SCHEMBL385931 0.88 OPRM1 (0.63) ADRB1ADRB3OPRM1OPRD1OPRK1
SCHEMBL388501 0.87 OPRM1 (0.50) OPRM1OPRD1OPRK1HRH3GRIN2D
SCHEMBL389427 0.86 OPRM1 (0.49) OPRM1OPRD1OPRK1HRH3GRIN2D
SCHEMBL387158 0.86 OPRM1 (0.61) ADRB1ADRB3OPRM1OPRD1OPRK1
SCHEMBL389044 0.85 OPRM1 (0.42) OPRM1OPRD1OPRK1GRIN2DGRIN3B
SCHEMBL388374 0.85 OPRM1 (0.42) OPRM1OPRD1OPRK1GRIN2DGRIN3B
SCHEMBL5712773 0.84 OPRM1 (0.43) ADRB1ADRB3OPRM1OPRD1OPRK1
SCHEMBL388826 0.84 OPRM1 (0.61) ADRB1ADRB3OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101638-B2 6-substituted nicotinamide derivatives as opioid receptor antagonists ELI LILLY AND COMPANY (US) 2012-01-24 US claimed
US-20090023785-A1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS PEDREGAL-TERCERO CONCEPCION 2009-01-22 US claimed
EP-1613597-B1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2007-11-07 EP claimed
US-20060205715-A1 6-Substituted nicotinamide derivatives as opioid receptor antagonists ELI LILLY AND COMPANY 2006-09-14 US claimed
US-8101638-B2 6-substituted nicotinamide derivatives as opioid receptor antagonists ELI LILLY AND COMPANY (US) 2012-01-24 US disclosed
US-20090023785-A1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS PEDREGAL-TERCERO CONCEPCION 2009-01-22 US disclosed
US-7399774-B2 6-substituted nicotinamide derivatives as opioid receptor antagonists ELI LILLY AND COMPANY (US) 2008-07-15 US disclosed
EP-1613597-B1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2007-11-07 EP disclosed
US-20060205715-A1 6-Substituted nicotinamide derivatives as opioid receptor antagonists ELI LILLY AND COMPANY 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205715-A1 6-Substituted nicotinamide derivatives as opioid receptor antagonists OPRM1, OPRL1, OPRK1 ADRB1 82/4885ADRB3 62/4885OPRM1 1/4885
US-20090023785-A1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS OPRM1, OPRK1, OPRD1 ADRB1 69/4885ADRB3 48/4885OPRM1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.